Gilead
Gilead’s HIV treatment meets primary trial endpoint
December 16, 2025Research and Development Gilead, HIV/AIDS
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
November 27, 2025Product launch Gilead, HIV/AIDS
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and Zambia, a milestone in the …
Gilead shares phase 3 results from HIV prevention trial
June 21, 2024Research and Development Gilead, HIV, Infections and infestations, clinical trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …
Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis
June 5, 2024Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar
Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …
Gilead and Arcus announce results from colorectal cancer treatment trial
June 3, 2024Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer
Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …
Gilead acquires XinThera to strengthen pipeline in oncology and inflammation
May 10, 2023Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …
‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access
July 19, 2021Sales and Marketing Cancer, Gilead, NHS, charity
The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge access to its new treatment …
Jubilant’s oral remdesivir formulation shows positive results in human trial
April 22, 2021COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir
Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …
Gilead’s bladder cancer drug gets FDA approval
April 15, 2021FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news
The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).
FDA approve Gilead’s breast cancer treatment after Phase III trial
April 8, 2021FDA, Gilead, Trodelvy, pharma, pharma news
The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).
Gilead and MSD partner to develop and commercialise two-drug HIV regimen
March 16, 2021Manufacturing and Production Gilead, HIV, MSD
Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …
Galapagos and Gilead halt Phase III trials for idiopathic pulmonary fibrosis drug
February 11, 2021Gilead
Galapagos and Gilead have halted the ISABELA Phase III clinical studies for their autotaxin inhibitor ziritaxestat in patients with idiopathic …
NICE recommends rheumatoid arthritis drug Jyseleca for NHS use
January 21, 2021Gilead, NICE
NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …
European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma
December 17, 2020Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus
Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …
Gilead’s lenacapavir meets primary goal in heavily treated and multidrug resistant HIV-1
November 19, 2020Research and Development Gilead, HIV, pharma
Gilead has pulled back the curtain on promising new data for its long-acting HIV-1 capsid inhibitor lenacapavir for heavily treated …
